eNOS-beta-actin interaction contributes to increased peroxynitrite formation during hyperoxia in pulmonary artery endothelial cells and mouse lungs.
Oxygen toxicity is the most severe side effect of oxygen therapy in neonates and adults. Pulmonary damage of oxygen toxicity is related to the overproduction of reactive oxygen species (ROS). In the present study, we investigated the effect of hyperoxia on the production of peroxynitrite in pulmonary artery endothelial cells (PAEC) and mouse lungs. Incubation of PAEC under hyperoxia (95% O(2)) for 24 h resulted in an increase in peroxynitrite formation. Uric acid, a peroxynitrite scavenger, prevented hyperoxia-induced increase in peroxynitrite. The increase in peroxynitrite formation is accompanied by increases in nitric oxide (NO) release and endothelial NO synthase (eNOS) activity. We have previously reported that association of eNOS with β-actin increases eNOS activity and NO production in lung endothelial cells. To study whether eNOS-β-actin association contributes to increased peroxynitrite production, eNOS-β-actin interaction were inhibited by reducing β-actin availability or by using a synthetic peptide (P326TAT) containing a sequence corresponding to the actin binding site on eNOS. We found that disruption of eNOS-β-actin interaction prevented hyperoxia-induced increases in eNOS-β-actin association, eNOS activity, NO and peroxynitrite production, and protein tyrosine nitration. Hyperoxia failed to induce the increases in eNOS activity, NO and peroxynitrite formation in COS-7 cells transfected with plasmids containing eNOS mutant cDNA in which amino acids leucine and tryptophan were replaced with alanine in the actin binding site on eNOS. Exposure of mice to hyperoxia resulted in significant increases in eNOS-β-actin association, eNOS activity, and protein tyrosine nitration in the lungs. Our data indicate that increased association of eNOS with β-actin in PAEC contributes to hyperoxia-induced increase in the production of peroxynitrite which may cause nitrosative stress in pulmonary vasculature.
Kondrikov
Dmitry
D
Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, Georgia 30912, USA.
Elms
Shawn
S
Fulton
David
D
Su
Yunchao
Y
D000199:Actins / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D019556:COS Cells; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D018496:Hyperoxia / Q000503:physiopathology; D015151:Immunoblotting; D008168:Lung / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018613:Microscopy, Confocal; D009569:Nitric Oxide / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III / Q000235:genetics / Q000378:metabolism*; D009842:Oligopeptides / Q000494:pharmacology; D010100:Oxygen / Q000494:pharmacology; D030421:Peroxynitrous Acid / Q000096:biosynthesis*; D011485:Protein Binding / Q000187:drug effects; D011651:Pulmonary Artery / Q000166:cytology; D034622:RNA Interference; D013481:Superoxides / Q000378:metabolism; D013552:Swine; D014443:Tyrosine / Q000378:metabolism
D000199:Actins; D009842:Oligopeptides; D013481:Superoxides; D030421:Peroxynitrous Acid; D009569:Nitric Oxide; D014443:Tyrosine; D052250:Nitric Oxide Synthase Type III; D010100:Oxygen
BioDrugs. 2001;15(12):801-17
11784212
J Clin Invest. 1997 Nov 1;100(9):2146-52
9410890
Am J Physiol Lung Cell Mol Physiol. 2000 Jun;278(6):L1204-12
10835326
Invest Ophthalmol Vis Sci. 2001 Jan;42(1):222-8
11133872
Nature. 1998 Apr 23;392(6678):821-4
9580552
Am J Physiol Lung Cell Mol Physiol. 2003 Jan;284(1):L26-38
12388366
Am J Physiol Cell Physiol. 2003 Sep;285(3):C546-54
12736139
J Biol Chem. 2007 Aug 10;282(32):23284-95
17562703
J Biol Chem. 2010 Feb 12;285(7):4319-27
19946124
Sci STKE. 2007 Sep 18;2007(404):pe52
17878410
Am J Physiol. 1999 Sep;277(3):L472-8
10484454
Crit Care Nurs Q. 2003 Jan-Mar;26(1):28-34
12669944
Plant Cell Physiol. 2006 Jun;47(6):689-97
16556649
Am J Respir Cell Mol Biol. 2006 Apr;34(4):453-63
16357365
J Leukoc Biol. 1994 Feb;55(2):253-8
8301222
Am J Respir Cell Mol Biol. 2001 Apr;24(4):390-7
11306431
J Biol Chem. 2006 Jan 20;281(3):1477-88
16257964
Br J Pharmacol. 1998 Dec;125(7):1455-62
9884073
Am J Physiol Cell Physiol. 2003 Jun;284(6):C1542-9
12734108
Am J Physiol Lung Cell Mol Physiol. 2003 Mar;284(3):L435-51
12573983
Intensive Care Med. 2004 Jun;30(6):1175-81
14963645
J Biol Chem. 2003 Feb 21;278(8):5894-901
12488320
J R Army Med Corps. 2000 Oct;146(3):185-90
11143686
Free Radic Biol Med. 2001 Nov 1;31(9):1075-83
11677040
Cell Biochem Biophys. 2005;43(3):439-49
16244368
Am J Respir Cell Mol Biol. 1998 Nov;19(5):819-25
9806747
Free Radic Biol Med. 2001 Dec 15;31(12):1624-32
11744337
Am J Physiol Lung Cell Mol Physiol. 2006 Jan;290(1):L41-50
16113046
Crit Care. 2007;11(4):R89
17714594
J Biol Chem. 1998 Sep 11;273(37):24025-9
9727019
Free Radic Biol Med. 2004 Jun 1;36(11):1460-70
15135183
Res Commun Mol Pathol Pharmacol. 1997 Apr;96(1):71-87
9178369
JAMA. 1991 Feb 27;265(8):1014-20
1992195